RT Journal Article
T1 Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort: JC virus seroprevalence in Spain
A1 Aladro, Yolandra
A1 Terrero, Rodrigo
A1 Cerezo García, Marta
A1 Ginestal, Rocardo
A1 Ayuso, Lucía
A1 Meca-Lallana, Virginia
A1 Millán, Jorge
A1 Borrego, Laura
A1 Martinez-Ginés, Marisa
A1 Rubio, Luisa
A1 De Andrés, Clara
A1 Miralles, Ambrosio
A1 Guijarro, Cristina
A1 Rodríguez-García, Elena
A1 García-Dominguez, José Manuel
A1 Muñoz-Fernández, Carmen
A1 López de Silanes, Carlos
A1 Gómez, Mayra
A1 Thuissard, Israel
A1 Cerdán, María
A1 Palmí, Itziar
A1 Díaz-Garzón, Luis Felipe
A1 Meca-Lallana, José
AB Objective: To estimate the seroprevalence of anti-JCV antibodies, seroconverting rates and evolution of antibody levels in a multiple sclerosis (MS) Spanish cohort. Methods: Multicenter, retrospective cross-sectional and longitudinal study. The JCV seroprevalence was analyzed in 711 MS patients by using 1st (STRATIFY-1) and 2nd generation (STRATIFY-2) two-step ELISA over 2.65 (±0.97) years. Seroconversion rate was obtained over 2 samples from 314 patients, and index stability from 301 patients with 3 or more samples available. The effect of each ELISA generation, demographics, clinical characteristics and therapy on seroprevalence was assessed by logistic regression. Results: The overall anti-JCV seroprevalence was 55.3% (51.6–58.9), similar across regions (p = 0.073). It increased with age (p b 0.000) and when STRATIFY-2 was used (60.5%, p = 0.001). Neither sex nor immunosuppressive therapy had any influence. Yearly seroconversion rate was 7% (considering only STRATIFY-2). Serological changes were observed in 24/301 patients, 5.7% initially seropositive reverted to seronegative and 7% initially seronegative changed to seropositive and again to seronegative, all these cases had initial index values around the assay's cut-off. Conclusions: JCV seroprevalence in Spanish MS patients was similar to that reported in other European populations. Changes in serostatus are not infrequent and should be considered in clinical decisions.
PB Elsevier
SN 0022-510X
YR 2016
FD 2016-06
LK https://hdl.handle.net/20.500.14352/132488
UL https://hdl.handle.net/20.500.14352/132488
LA eng
NO Aladro, Y., Terrero, R., Cerezo, M., Ginestal, R., Ayuso, L., Meca-Lallana, V., Millán, J., Borrego, L., Martinez-Ginés, M., Rubio, L., De Andrés, C., Miralles, A., Guijarro, C., Rodríguez-García, E., García-Dominguez, J. M., Muñoz-Fernández, C., López De Silanes, C., Gómez, M., Thuissard, I., et al. (2016). Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort JC virus seroprevalence in Spain. Journal of the Neurological Sciences, 365, 16-21. https://doi.org/10.1016/J.JNS.2016.03.050
NO Referencias bibliográficas:•	M.W. Ferenczy, L.J. Marshall, C.D. Nelson, W.J. Atwood, A. Nath, K. Khalili, and et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain Clin. Microbiol. Rev. 25 2012 471 506•	H.S. Wollebo, M.K. Vhite, J. Gordon, J.R. Berger, and K. Khalili Persistence and pathogenesis of the neurotropic polyomavirus JC Ann. Neurol. 77 2015 560 570•	C.H. Polman, P.W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, D.H. Miller, and et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N. Engl. J. Med. 354 2006 899 910•	O. Outteryck, J.C. Ongagna, B. Brochet, L. Rumbach, C. Lebrun-Frenay, M. Debouverie, and et al. A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort Eur. J. Neurol. 21 2014 40 48•	L. Gorelik, M. Lerner, S. Bixler, M. Crossman, B. Sclain, K. Simon, and et al. Anti-JC virus antibodies: implications for PML risk stratification Ann. Neurol. 68 2010 295 303•	T. Plavina, M. Subramanyam, G. Bloomgren, S. Richman, A. Pace, S. Lee, and et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy Ann. Neurol. 76 2014 802 812•	D.C. Landy, and E.M. Hecht Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis Clin. Neuropharmacol. 37 2014 45 51•	G. Bloomgren, S. Richman, C. Hotermans, M. Subramanyam, S. Goelz, A. Natarajan, and et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy N. Engl. J. Med. 366 2012 1870 1880•	C. Bozic, S. Richman, T. Plavina, A. Natarajan, J. Scanlon, M. Subramanyam, and et al. Anti-JCV antibody prevalence in patients with relapsing multiple sclerosis receiving or considering treatment with natalizumab: baseline results of STRATIFY-2 Neurology 78 2012 [Meeting Abstracts 1]: S41.002•	Available from: http://www.fda.gov/Drugs/DrugSafety/ucm366529.htm. Accessed 13 September 2014.•	T. Rosenkranz, M. Novas, and C. Terborg PML in a patient with lymphocytopenia treated with dimethyl fumarate N. Engl. J. Med. 372 2015 1476 1478•	M. Faulkner Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis Expert Opin. Drug Saf. 14 2015 1737 1748•	P. Lee, T. Plavina, A. Castro, M. Berman, D. Jaiswal, S. Rivas, and et al. A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification J. Clin. Virol. 57 2013 141 146•	C. Bozic, S. Richman, T. Plavina, M.S. Natarajan, J.V. Scanlon, M. Subramanyam, and et al. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baselina results of STRATFY-1 Ann. Neurol. 70 2011 742 750•	A.K. Trampe, C. Hemmelmann, A. Stroet, A. Haghikia, K. Hellwig, H. Wiendl, and et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort Neurology 78 2012 1736 1742•	L. Moiola, F. Sangalli, and V. Martinelli Prevalence of anti-JCV antibodies in a cohort of natalizumab-treated multiple sclerosis patients from Italy Neurology 76 2011 S30.007•	O. Outteryck, J.C. Ongagna, A. Duphamel, H. Zéphir, N. Collongues, A. Lacour, and et al. Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy J. Neurol. 259 2012 2293 2298•	T. Olsson, A. Achiron, L. Alfredsson, T. Berger, D. Brassat, A. Chan, and et al. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort Mult. Scler. 19 2013 1533 1538•	C. Bozic, M. Subramanyam, S. Richman, T. Plavina, A. Zhang, and B. Ticho Anti-JC virus (JCV) antibody prevalence in the JVC epidemiology in MS (JEMS) trial Eur. J. Neurol. 21 2014 299 304•	C. Warnke, R. Ramanujam, T. Plavina, T. Bergström, S. Goelz, M. Subramanyam, and et al. Changes to anti-JCV antibody levels in a Swedish national MS cohort J. Neurol. Neurosurg. Psychiatry 84 2013 1199 1205•	M. Kolasa, S. Hagman, A. Verkkoniemi-Ahola, L. Airas, K. Koivisto, and I. Elovaara Anti-JC virus seroprevalence in a Finnish MS cohort Acta Neurol. Scand. 2015 10.1111/ane.12475•	M.I. Dominguez-Mozo, M. García-Montojo, V. De Las Heras, A. García-Martínez, A.M. Arias-Leal, I. Casanova, and et al. Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish multiple sclerosis patients treated with natalizumab J. NeuroImmune Pharmacol. 8 2013 1277 1286•	A. Martins da Silva, M.E. Santos, and on behalf of the Portuguese JEMS study investigators JCV epidemiology in MS (JEMS)-epidemiology of anti-JCV antibody prevalence in multiple sclerosis patients-Portuguese data J. Neurol. Sci. 337 2014 119 122•	O. Outteryck, H. Zéphir, J. Salleron, J.C. Ongagna, A. Etxeberria, N. Collongues, and et al. JC virus seroconversion in multiple sclerosis patients receiving natalizumab Mult. Scler. 20 2014 822 829•	R. Alroughani, S. Akhtar, S.F. Ahmed, S.J. Khoury, J.Y. Al-Hashel, M.A. Sharaian, and et al. JC virus seroprevalence and seroconversion in multiple sclerosis cohort: a Middle-Eastern study J. Neurol. Sci. 360 2016 61 65•	A. Antonsson, M. Pawlita, M.C.W. Feltkamp, J.N. Bouwes Bavinck, S. Euvrard, A. Catherine, and et al. Longitudinal study of seroprevalence and serostability of the human polyomaviruses JCV and BKV in organ transplant recipients J. Med. Virol. 85 2013 327 335
DS Docta Complutense
RD 26 feb 2026